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We have shown that serine binds to an amino acid
binding pocket located in the A domain of each PKM2
monomer, but the molecular mechanism by which it
modifies PKM2 activity is still unknown, especially
regarding the switch from dimer to tetramer. While
fructose 1,6 bisphosphate (FBP) activates PKM2 by pro-
moting tetramerization, it is not clear if serine is able to
modulate the oligomerization status of PKM2 since it
binds to a completely different region of the protein. In
order to understand whether serine can induce PKM2
tetramerization similarly to FBP, we looked at the oligo-
meric state of recombinant purified PKM2 under native
conditions by HPLC-UV SEC (size exclusion chromato-
graphy). We tested the effects of increasing concentra-
tions of L-Serine on the oligomeric state of PKM2.
Additionally, in order to understand whether PKM2
activation by serine may be mediated or affected by the
oligomeric state of the protein, we tested if serine is
able to activate PKM2 even when tetramerization is
impaired. For that purpose, we generated several mono-
mer-monomer and dimer-dimer interface mutants
aimed to disrupt the ability of PKM2 to tetramerize. By
using HPLC-UV SEC we have been able to see changes
in the oligomeric state of wild type PKM2 and we have
confirmed that FBP induces its tetramerization. We have
generated the S437Y PKM2 mutant that cannot bind FBP
and an additional, H464A mutant that cannot bind ser-
ine. Our in vitro activity assays indicate that PKM2 bind-
ing to FBP is required also to fully activate the protein in
the presence of serine. We also determined the oligo-
meric state of the S437Y and H464A mutants in the pre-
sence of different concentrations of serine and FBP to
investigate the possibility of a dependency between the
two mechanisms of activation and how it relates to the
oligomeric state of PKM2.
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